Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The landscape of rare diseases is constantly changing as new ailments and conditions are identified and reported regularly.

FOR the 6,000 people in the UK who are newly diagnosed with bile duct cancer every year, the prognosis is uniquely grim.

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.

In the new study, patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal ...

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important ...